Research presented by Dr Erik Sahai has shown that early, reversible diversity in tumour cell state can blunt the effect of protein kinase B inhibition in triple negative breast cancer.

Vaderis Therapeutics’ goal to develop the first drug aimed specifically at a certain rare blood vessel disorder came one step closer today with the news that the therapy is safe and reduced nosebleeds ...